Phreesia (NYSE:PHR) General Counsel Allison Hoffman Sells 6,176 Shares of Stock

Key Points

• General Counsel Allison Hoffman sold 6,176 shares of Phreesia on March 23 at an average price of $11.97 for about $73,927, leaving her with 163,485 shares (a 3.64% reduction) valued at roughly $1.96M.
• Phreesia shares trade around $11.24, close to a 52-week low of $10.75 and well below the 52-week high of $32.76; the company has a market cap of about $677.8M and a negative P/E of -112.42.
• Analysts hold a consensus rating of "Moderate Buy" (17 Buys, 1 Hold, 1 Sell) with an average price target of $28.94, although several firms have recently trimmed targets (e.g., JPMorgan cut its target from $29 to $24).

Phreesia, Inc. (NYSE:PHR - Get Free Report) General Counsel Allison Hoffman sold 6,176 shares of Phreesia stock in a transaction on Monday, March 23rd. The stock was sold at an average price of $11.97, for a total transaction of $73,926.72. Following the completion of the transaction, the general counsel directly owned 163,485 shares of the company's stock, valued at approximately $1,956,915.45. This represents a 3.64% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Phreesia Stock Performance

Shares of NYSE:PHR traded down $0.04 on Wednesday, reaching $11.24. 916,118 shares of the company's stock were exchanged, compared to its average volume of 1,634,837. The business's 50-day moving average is $12.91 and its two-hundred day moving average is $18.10. The company has a quick ratio of 2.44, a current ratio of 2.44 and a debt-to-equity ratio of 0.01. Phreesia, Inc. has a fifty-two week low of $10.75 and a fifty-two week high of $32.76. The firm has a market capitalization of $677.84 million, a price-to-earnings ratio of -112.42 and a beta of 0.67.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the company. Wall Street Zen downgraded Phreesia from a "strong-buy" rating to a "buy" rating in a research note on Sunday, February 8th. Weiss Ratings restated a "sell (e+)" rating on shares of Phreesia in a research report on Wednesday, January 28th. Royal Bank Of Canada assumed coverage on Phreesia in a research note on Friday, January 9th. They set a "moderate buy" rating and a $26.00 price objective for the company. JPMorgan Chase & Co. dropped their target price on Phreesia from $29.00 to $24.00 and set an "overweight" rating on the stock in a research report on Friday, February 20th. Finally, DA Davidson reduced their price target on shares of Phreesia from $35.00 to $30.00 and set a "buy" rating for the company in a report on Friday, January 23rd. Seventeen investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $28.94.

Hedge Funds Weigh In On Phreesia

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Federated Hermes Inc. bought a new stake in Phreesia during the 3rd quarter valued at $32,000. Asset Management One Co. Ltd. bought a new position in shares of Phreesia in the third quarter worth $45,000. Van ECK Associates Corp increased its holdings in shares of Phreesia by 78.7% during the fourth quarter. Van ECK Associates Corp now owns 2,502 shares of the company's stock valued at $42,000 after purchasing an additional 1,102 shares during the period. Rockefeller Capital Management L.P. raised its stake in shares of Phreesia by 354.6% during the fourth quarter. Rockefeller Capital Management L.P. now owns 2,755 shares of the company's stock valued at $47,000 after purchasing an additional 2,149 shares in the last quarter. Finally, KBC Group NV raised its stake in shares of Phreesia by 83.4% during the fourth quarter. KBC Group NV now owns 3,449 shares of the company's stock valued at $58,000 after purchasing an additional 1,568 shares in the last quarter. 92.10% of the stock is owned by institutional investors.

Phreesia Company Profile

Phreesia, Inc NYSE: PHR is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company's cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.

Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.